Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24282688 | 1.00 | CYP2C19 (0.42) | CYP2C19GRM5TDP1ALDH1A1POLB | |
| SCHEMBL21057707 | 1.00 | CYP2C19 (0.42) | CYP2C19GRM5TDP1ALDH1A1POLB | |
| SCHEMBL21057704 | 1.00 | CYP2C19 (0.42) | CYP2C19GRM5TDP1ALDH1A1POLB | |
| SCHEMBL21057971 | 0.85 | ITGB3 (0.33) | ALDH1A1POLBLMNA | |
| SCHEMBL21057975 | 0.85 | ITGB3 (0.33) | ALDH1A1POLBLMNA | |
| SCHEMBL21057974 | 0.85 | ITGB3 (0.33) | ALDH1A1POLBLMNA | |
| SCHEMBL21057926 | 0.83 | LMNA (0.40) | ALDH1A1LMNA | |
| SCHEMBL21057931 | 0.83 | LMNA (0.40) | ALDH1A1LMNA | |
| SCHEMBL21138517 | 0.83 | LMNA (0.40) | ALDH1A1LMNA | |
| SCHEMBL21057929 | 0.83 | LMNA (0.40) | ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12344605-B2 | Substituted pyrrolidine amides II | GRUENENTHAL GMBH (DE) | 2025-07-01 | — | — | US | disclosed |
| US-20220127264-A1 | SUBSTITUTED PYRROLIDINE AMIDES II | GRUENENTHAL GMBH (DE) | 2022-04-28 | — | — | US | disclosed |
| EP-3728233-B1 | SUBSTITUTED PYRROLIDINE AMIDES II | GRUENENTHAL GMBH (DE) | 2022-04-20 | — | — | EP | disclosed |
| EP-3728219-B1 | SUBSTITUTED PYRROLIDINE AMIDES I | GRUENENTHAL GMBH (DE) | 2022-04-13 | — | — | EP | disclosed |
| EP-3728219-A1 | SUBSTITUTED PYRROLIDINE AMIDES I | Grünenthal GmbH (DE) | 2020-10-28 | — | — | EP | disclosed |
| EP-3728233-A1 | SUBSTITUTED PYRROLIDINE AMIDES II | Grünenthal GmbH (DE) | 2020-10-28 | — | — | EP | disclosed |
| CN-111556867-A | Substituted pyrrolidine amides I | 格吕伦塔尔有限公司 | 2020-08-18 | — | — | CN | disclosed |
| CN-111491931-A | Substituted pyrrolidine amides II | 格吕伦塔尔有限公司 | 2020-08-04 | — | — | CN | disclosed |
| US-10626106-B2 | Substituted pyrrolidine amides I | GRUENENTHAL GMBH (DE) | 2020-04-21 | — | — | US | disclosed |
| US-20190185455-A1 | Substituted Pyrrolidine Amides I | GRUENENTHAL GMBH (DE) | 2019-06-20 | — | — | US | disclosed |
| US-20190185470-A1 | Substituted Pyrrolidine Amides II | GRUENENTHAL GMBH (DE) | 2019-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190185470-A1 | Substituted Pyrrolidine Amides II | NR3C1, NR3C2, MC2R | CYP2C19 331/4885GRM5 22/4885TDP1 3722/4885 |
| US-10626106-B2 | Substituted pyrrolidine amides I | NR3C1, NR3C2, NR5A1 | CYP2C19 319/4885GRM5 23/4885TDP1 3265/4885 |
| US-20220127264-A1 | SUBSTITUTED PYRROLIDINE AMIDES II | NR3C1, NR3C2, MC2R | CYP2C19 331/4885GRM5 22/4885TDP1 3722/4885 |
| US-12344605-B2 | Substituted pyrrolidine amides II | NR3C1, NR3C2, MC2R | CYP2C19 331/4885GRM5 22/4885TDP1 3722/4885 |
| US-20190185455-A1 | Substituted Pyrrolidine Amides I | NR3C1, NR3C2, NR5A1 | CYP2C19 319/4885GRM5 23/4885TDP1 3265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.